Neuropsychiatric Drugs Market Size, Share & Trends Analysis Report By Drug Type (Typical Antipsychotics and Atypical Antipsychotics), By Indication, By Route Of Administration, Region And Segment Forecasts, 2025-2034.
Neuropsychiatric Drugs Market is expected to grow at a 5.0% CAGR during the forecast period for 2025-2034.
Neuropsychiatric disorders are psychological disorder occur owing to a functional disturbance in the cerebral system. According to the National Institutes of Health, Neuropsychiatric disorders are one of the top 10 leading causes of global disability-adjusted life years (DALYs). The neuropsychiatry is concerned with illnesses of behavior and cognition that arise from evident disorder in cerebral function or indirect effects of the extracerebral disease. Among people age more than 65, neuropsychiatric is the most common disorder. The rising prevalence of neuropsychiatric disorders globally and rising demand for advanced treatment are some of the key factors propelling the growth of the neuropsychiatric drugs market.
Psychiatric and neurological disorders are progressively important in society, mainly due to growing incidence rates of these disorders in adolescents and children and demographic changes. According to Leibniz Institute for Prevention Research and Epidemiology – BIPS, in 2015, about 38% of EU citizens, that is 165 million, suffered from a minimum of one disease from the neuropsychiatric range. Neuropsychiatric diseases are the key cause of impairment and disability of quality of life and capability to function. In Europe, more than 42% of years spent with a disability are attributed to neuropsychiatric disorders.
The Global Neuropsychiatric Drugs Market has a marvelous opportunity to grow during the estimated timeframe. The growing research and development activities for the development of novel treatment for neuropsychiatric disorders and the presence of a strong pipeline of these drugs are expected to propel the demand for neuropsychiatric disorder drugs during the forecast period. For instance, in January 2020, a clinical-stage biopharmaceutical company BlackThorn Therapeutics focused on evolving targeted drugs for the treatment of central nervous system (CNS) disorders has announced the progression of Phase 2 clinical trial for its BTRX-335140 (BTRX-140), a selective antagonist for the kappa opioid receptor (KOR). The introduction of advanced medicines for the treatment of neuropsychiatric disorders is estimated to propel the global demand for these drugs in the coming years. Additionally, the growing demand for cost-effective drugs for neuropsychiatric disorders is expected to boost the demand for neuropsychiatric drugs during the forecast period. However, side effects such as blurred vision, drowsiness, and insomnia caused by these drugs may restrain the growth of the neuropsychiatric drugs market during the forecast period.
Market Segmentation
The Global Neuropsychiatric Drugs Market is segmented on the basis of drug type, indication, route of administration, and region. Based on the drug type, the market is divided into typical antipsychotics, and atypical antipsychotics. The typical antipsychotics include, Prochlorperazine, Haloperidol, and other drugs. Based on atypical antipsychotics, the market is segmented into, Aripiprazole, Asenapine, Cariprazine, Clozapine, Lurasidone, Olanzapine, Risperidone, and other drugs. On the basis of indication, the market is categorized into bipolar disorder, schizophrenia, psychotic depression, and others. By route of administration, the neuropsychiatric drugs market is segmented into parenteral and oral route. Based on region, the market is studied across Asia-Pacific, North America, LAMEA, and Europe. Among that, North America held the largest share of the market, followed by Europe in 2019. In terms of growth rate, Asia Pacific is expected to grow at a significant CAGR during the estimated timeframe.
Competitive Landscape
Some of The Key Players in The Neuropsychiatric Drugs Market:
- Novartis
- Pfizer
- Otsuka
- Allergan
- Eli Lilly
- Sunovion
- AstraZeneca
- Actavis Laboratories
- Johnson & Johnson
- Bristol Myers Squibb
- Sage Therapeutics
- BlackThorn Therapeutics
- BioXcel Therapeutics
- Lundbck A/S
- Takeda
- Cerevel Therapeutics, LLC
- INmune Bio
- Perception Neuroscience
- Psilera Bioscience
- Eleusis Holdings Ltd
- Other Prominent Players
The Neuropsychiatric Drugs Market Report Scope
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 5.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Type, By Indication, By Route of Administration |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Novartis, Pfizer, Otsuka, Allergan, Eli Lilly, Sunovion, AstraZeneca, Actavis Laboratories, Johnson & Johnson, and Bristol Myers, Sage Therapeutics, BlackThorn Therapeutics, H. Lundbeck A/S, Takeda, Cerevel Therapeutics, LLC, among others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Neuropsychiatric Drugs Market Segmentation:
Global Neuropsychiatric Drugs Market by Drug Type
- Typical Antipsychotics
- Prochlorperazine
- Haloperidol
- Others
- Atypical Antipsychotics
- Aripiprazole
- Asenapine
- Cariprazine
- Clozapine
- Lurasidone
- Olanzapine
- Risperidone
- Others
Global Neuropsychiatric Drugs Market Based on Indication
- Schizophrenia
- Bipolar Disorder
- Psychotic Depression
- Others
Global Neuropsychiatric Drugs Market Based on Route of Administration
- Oral
- Parenteral
Global Neuropsychiatric Drugs Market Based on Region
Europe Neuropsychiatric Drugs Market by Country
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
North America Neuropsychiatric Drugs Market by Country
- U.S.
- Canada
Asia Pacific Neuropsychiatric Drugs Market by Country
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Neuropsychiatric Drugs Market by Country
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Neuropsychiatric Drugs Market by Country
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Neuropsychiatric Drugs Market is expected to grow at a 5.0% CAGR during the forecast period for 2025-2034.
Novartis, Pfizer, Otsuka, Allergan, Eli Lilly, Sunovion, AstraZeneca, Actavis Laboratories, Johnson & Johnson, and Bristol Myers, Sage Therapeutics, B
Drug Type, Indication and Route of Administration are the key segments of the Neuropsychiatric Drugs Market.
North American region is leading the Neuropsychiatric Drugs Market.